Industries > Pharma > The Prostate Cancer Therapeutics Market Forecast 2014-2024
The Prostate Cancer Therapeutics Market Forecast 2014-2024
Opportunities for Leading Companies
Where is the prostate cancer therapeutics market heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.
Our 208-page report provides 160 tables, charts, and graphs. Our new study lets you assess leading drugs and devices in the prostate cancer therapeutics market, showing their prospects to 2024. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.
Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of four exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
– Professor Malcolm Mason, Cancer Research UK
– Hans Kolam, Chief Financial Officer and Helen Tuvesson, Chief Scientific Officer, Active Biotech
– Dr. Estuardo Aguilar-Cordova, Co-Founder, CEO and Chairman, Advantagene
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see revenue forecasts to 2024 for the main submarkets:
• Prostate cancer drugs
• Prostate cancer devices
Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.
See revenue forecasts for prostate cancer drugs and devices
How will leading drugs perform to 2024 at the world level? Our study forecasts sales of 9 leading prostate cancer drugs, including these:
• Zytiga sales forecast 2014-2024
• Lupron sales forecast 2014-2024
• Xtandi sales forecast 2014-2024
• Zoladex sales forecast 2014-2024
• Casodex sales forecast 2014-2024
• Jevtana sales forecast 2014-2024
• Provenge sales forecast 2014-2024
• Taxotere sales forecast 2014-2024
• Xofigo sales forecast 2014-2024
Our new study also discusses promising drugs in the late stages of development.
How will the prostate cancer devices market perform to 2024? Our study forecasts sales for the main device submarkets, including these:
• The brachytherapy market forecast 2014-2024
• The radical prostatectomy market forecast 2014-2024
• The external beam radiation market forecast 2014-2024
• The cryotherapy market forecast 2014-2024
• The HIFU market forecast 2014-2024
Discover how high revenues can go. You see what's happening, understanding trends, challenges and opportunities.
Our analysis also breaks the main world market into geographical markets.
What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 13 national markets to 2024:
• Rest of Europe
• South Korea
• Rest of the World
There will be growth in established pharmaceutical and medical devices markets and in developing countries. Our analyses show that India, Brazil, China and Mexico, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.
Leading companies and potential for market growth
Overall world revenue for prostate cancer therapeutics will reach $7bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for prostate cancer drugs and procedures, expanding healthcare coverage and the success of novel diagnostics will increase sales to 2024.
Our work shows you what organisations hold greatest potential. See profiles of 7 leading companies, including these:
• Johnson and Johnson
• Varian Medical Systems
• Theragenics Corporation (Juniper)
A company profile gives you the following information:
• Discussion of a company’s activities and outlook
• Recent financial results
• Assessment of recent developments – mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures.
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the prostate cancer therapeutics market?
Our new report discusses issues and events affecting the prostate cancer therapeutics market. You will find discussions, including qualitative analyses:
• Drugs targeting mCRPC – driving market growth
• Strong pipeline of drugs in development
• Robotic prostatectomy – showing strong growth
• Prostate cancer market driven by an aging population
• International expansion – targeting emerging national markets
• Stem cells – offering opportunities for growth
• High rivalry among competitors
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How The Prostate Cancer Therapeutics Market Forecast 2014-2024: Opportunities for Leading Companies report helps you
In summary, our 208-page report gives you the following knowledge:
• Revenues forecast to 2024 for the world prostate cancer therapeutics market and its submarkets – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2024 for the leading 13 national markets – US, Japan, China, Germany, France, UK, Italy, Spain, Rest of Europe, India, Brazil, Russia, Mexico, South Korea and Rest of the World
• Assessment of 7 leading companies – hear about products, results and strategies
• Predicted revenues of 9 leading drugs and 5 medical procedures to 2024 – see potentials of top products
• Review of R&D pipelines – investigate developmental trends and progress
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
• View opinions from our survey, seeing interviews with authorities
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the prostate cancer therapeutics market and leading companies. You find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6